Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Ä«Å×°í¸®
ÆÄ¸Ó½´Æ¼Äà (4512)
°¨¿°Áúȯ (322)
°ñÁúȯ Ä¡·á (48)
´ç´¢º´ (164)
¹é½Å (169)
ºñ¸¸Ä¡·á/´ÙÀÌ¾îÆ® (49)
ºñó¹æ ÀǾàǰ (149)
¼öÀÇÇÐ (17)
½Å°æÁúȯ (179)
½Å¾à°³¹ß (1306)
¾ÏÄ¡·á (856)
¾à¹°Àü´Þ (179)
ÀǾàǰ ±ÔÁ¦È¯°æ (105)
Á¤½ÅÁúȯ (88)
Á¦³×¸¯ ÀǾàǰ (116)
Á¦¾àȸ»çºÐ¼® (488)
󹿾à (128)
Áö¿ªº°°Ë»ö
ÃâÆÇ»ç¿¡¼­ ã±â

½Å¾à°³¹ß ½ÃÀåÁ¶»çº¸°í¼­

½Å¾à°³¹ß ½ÃÀåÀ» Á¶»ç ºÐ¼®ÇÑ ÀÚ·á·Î ½ÃÀå ±Ô¸ð, »ê¾÷ ºÐ¼®, ÇâÈÄ ½ÃÀå ¿¹Ãø µîÀÇ ³»¿ëÀ» ´Ù·ç°í ÀÖ½À´Ï´Ù.
º¸°í¼­¿¡ µû¶ó¼­ ÁÖ¿ä ±â¾÷ ºÐ¼®, °æÀïȯ°æ ºÐ¼®, ¿¬±¸°³¹ß ÇöȲ, ¿µ¾÷ Àü·«, ±â¾÷ Á¦ÈÞ ÇöȲÀ» Æ÷ÇÔÇÏ´Â °æ¿ìµµ ÀÖ½À´Ï´Ù.

»ó¼¼ºÐ·ù
Á¦¸ñ°Ë»ö
1 - 25 ¸®ºä (Àüü£º 1300 °Ç) Á¤·Ä Ç¥½Ã °Ç¼ö
Antibiotic Resistance 2012: The Antibiotic Development Pipeline and Strategies to Combat Antibiotic Resistance
»ùÇÃ
»óǰÄÚµå :228337
¼¼°èÀÇ Ç×»ý¹°Áú ³»¼º(Antibiotic Resistance) ½ÃÀåÀ» Æ÷°ýÀûÀ¸·Î Á¶»çÇϰí, Ç×»ý¹°Áú ÆÄÀÌÇÁ¶óÀÎ ¹× ³»¼º ¸ÞÄ¿´ÏÁò¿¡ ´ëÇ×ÇÏ´Â ½ÅÀü·«À» ºÐ¼®ÇÏ¿© ±¹°¡º° µ¿Çâ, Ãâ½Ã Á¦Ç° ºÐ¼® µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 2,300
¹ßÇàÀÏ 2012³â 01¿ù
¸®¼­Ä¡»ç BioPharm Reports (Technology and Markets Ltd)
ÆäÀÌÁö¼ö 120 Pages
Liver Transplantation Global Clinical Trials Review, H1, 2012
»ùÇÃ
»óǰÄÚµå :228198
°£ À̽Ŀ¡ °üÇÑ ÃֽŠÀÓ»ó ¿¬±¸ µ¿Çâ¿¡ ´ëÇØ ºÐ¼®ÇßÀ¸¸ç, Ä¡·á¹ý °³¿ä, G7 ±¹°¡¡¤BRICS ±¹°¡¡¤E7 ±¹°¡ÀÇ ÀÓ»ó½ÃÇè »óȲ, Áö¿ª¡¤»ó¡¤´Ü°èº° ÁøÇà »óȲ, À¯·Â ½ºÆù¼­, °¢ ±â¾÷ ¹× ¿¬±¸±â°üÀÇ ¿¬±¸ ÁøÇà »óȲ, À¯·Â ¾àÁ¦ ºñ±³ µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 1,000
¹ßÇàÀÏ 2012³â 01¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 104
Systemic Sclerosis (Scleroderma) Global Clinical Trials Review, H1, 2012
»ùÇÃ
»óǰÄÚµå :228197
Àü½Å¼º °æÈ­Áõ(°æÇÇÁõ)¿¡ °üÇÑ ÀÓ»ó ¿¬±¸ÀÇ Ãֽе¿Çâ¿¡ ´ëÇØ ºÐ¼®ÇßÀ¸¸ç, Áúȯ °³¿ä, G7 ±¹°¡¡¤BRICS ±¹°¡¡¤E7 ±¹°¡ÀÇ ÀÓ»ó½ÃÇè »óȲ, Áö¿ª¡¤»ó¡¤´Ü°èº° ÁøÇà »óȲ, À¯·Â ½ºÆù¼­, °¢ ±â¾÷ ¹× ¿¬±¸±â°üÀÇ ¿¬±¸ ÁøÇà »óȲ, À¯·Â ¾àÁ¦ ºñ±³ µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 1,000
¹ßÇàÀÏ 2012³â 01¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 95
Iliac Aneurysms Global Clinical Trials Review, H1, 2012
»ùÇÃ
»óǰÄÚµå :226836
Àå°ñ µ¿¸Æ·ù(Iliac Aneurysms) Ä¡·áÁ¦ °ü·Ã ÀÓ»ó½ÃÇè µ¿Çâ¿¡ ´ëÇØ Á¶»çÇϰí, ÀÓ»ó½ÃÇè °Ç¼ö ¹× ÇÇÇèÀÚ ¼ö, ´Ü°èº°, »ó(ßÓ)º° »óȲ, À¯¸Á ±â¾÷, °³¹ßÁßÀÎ Ä¡·áÁ¦ Á¤º¸, ÀÓ»ó½ÃÇè °³¿ä µîÀ» Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 1,000
¹ßÇàÀÏ 2012³â 01¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 43
Graft Versus Host Disease (GVHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
»ùÇÃ
»óǰÄÚµå :227732
¼¼°è ÀÌ½ÄÆí´ë ¼÷ÁÖÁúȯ (GVHD) Ä¡·áÁ¦ ½ÃÀåÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡°ú °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀ» Æò°¡ºÐ¼®ÇßÀ¸¸ç, ÇâÈÄ ½ÃÀå°æÀï, ±â¾÷ °³¿ä¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,995
¹ßÇàÀÏ 2012³â 01¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 74
Venous Thromboembolism (VTE) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
»ùÇÃ
»óǰÄÚµå :227731
¼¼°è Á¤¸ÆÇ÷Àü»öÀüÁõ(VTE) Ä¡·áÁ¦ ½ÃÀåÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡°ú °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀ» Æò°¡ºÐ¼®ÇßÀ¸¸ç, ÇâÈÄ ½ÃÀå°æÀï, ±â¾÷ °³¿ä¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,995
¹ßÇàÀÏ 2012³â 01¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 75
Eczema Therapeutics - Pipeline Assessment and Market Forecasts to 2018
»ùÇÃ
»óǰÄÚµå :227730
¼¼°è ½ÀÁø Ä¡·áÁ¦ ½ÃÀåÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡°ú °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀ» Æò°¡ºÐ¼®ÇßÀ¸¸ç, ÇâÈÄ ½ÃÀå°æÀï, ±â¾÷ °³¿ä¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2012³â 01¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 76
Overactive Bladder (OAB) Therapeutics - Pipeline Assessment and Market Forecasts to 2019
»ùÇÃ
»óǰÄÚµå :227729
¼¼°èÀÇ °ú¹Î¼º ¹æ±¤(OAB) Ä¡·áÁ¦ ½ÃÀåÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡°ú °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀ» Æò°¡ºÐ¼®ÇßÀ¸¸ç, ÇâÈÄ ½ÃÀå°æÀï, ±â¾÷ °³¿ä¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,995
¹ßÇàÀÏ 2012³â 01¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 87
Gaucher's Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018
»ùÇÃ
»óǰÄÚµå :227726
¼¼°è °í¼Îº´ Ä¡·áÁ¦ ½ÃÀåÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡°ú °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀ» Æò°¡ºÐ¼®ÇßÀ¸¸ç, ÇâÈÄ ½ÃÀå°æÀï, ±â¾÷ °³¿ä¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2012³â 01¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 66
Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
»ùÇÃ
»óǰÄÚµå :227725
¼¼°è Á׻󵿸ưæÈ­Áõ/°ü»óµ¿¸ÆÁúȯ(CAD) Ä¡·áÁ¦ ½ÃÀåÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡°ú °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀ» Æò°¡ºÐ¼®ÇßÀ¸¸ç, ÇâÈÄ ½ÃÀå°æÀï, ±â¾÷ °³¿ä¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2012³â 01¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 111
Endpoints-Clinical Trials in Orphan Diseases - Highest Number of Terminated Trials Focused on Mulitiple Myeloma
»ùÇÃ
»óǰÄÚµå :227589
ÁÖ¿ä 7°³ Èñ±ÍÁúȯ(ÇåÆÃÅϺ´, ±Þ¼º °ñ¼ö¼º ¹éÇ÷º´, ·ç°Ô¸¯º´(ALS), È£ÁöŲ ¸²ÇÁÁ¾, ´Ù¹ß¼º °ñ¼öÁ¾, ³­¼Ò¾Ï, ÃéÀå¾Ï)ÀÇ ÀÓ»ó½ÃÇè ¿£µåÆ÷ÀÎÆ®¿¡ ´ëÇØ Á¶»çºÐ¼®ÇßÀ¸¸ç, ÁÖ¿ä ¾àÁ¦ ºÐ¼®, ÀÓ»ó½ÃÇè ºÐ¼®, ÁÖ¿ä ±â¾÷ °³¿ä µî¿¡ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2012³â 01¿ù
¸®¼­Ä¡»ç GBI Research
ÆäÀÌÁö¼ö Pages: 118
Pancreatic Cancer Global Clinical Trials Review, H2, 2011
»ùÇÃ
»óǰÄÚµå :228234
¼¼°èÀÇ ÃéÀå¾Ï(Pancreatic Cancer) ÀÓ»ó½ÃÇèÀ» Á¶»çÇϰí, Áö¿ªº° ÀÓ»ó½ÃÇè °Ç¼ö µ¥ÀÌÅÍ, ½ÃÇè ´Ü°è, ½ÃÇè »óȲ, ä¿ë ÁÖÁ¦ ¹× ½ºÆù¼­ ±â¾÷ Á¾·ùº° ÀÓ»ó½ÃÇè µ¥ÀÌÅÍ, Áß´Ü(ÀϽÃÁßÁö, ÆóÁö, Á¾·á)µÈ ½ÃÇè ¸ñ·Ï µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 1,000
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 124
Arteriosclerosis Global Clinical Trials Review, H2, 2011
»ùÇÃ
»óǰÄÚµå :228200
µ¿¸Æ°æÈ­Áõ¿¡ °üÇÑ ÃֽŠÀÓ»ó ¿¬±¸ µ¿Çâ¿¡ ´ëÇØ ºÐ¼®ÇßÀ¸¸ç, Áúȯ °³¿ä, G7 ±¹°¡¡¤BRICS ±¹°¡¡¤E7 ±¹°¡ÀÇ ÀÓ»ó½ÃÇè »óȲ, Áö¿ª¡¤»ó¡¤´Ü°èº° ÁøÇà »óȲ, À¯·Â ½ºÆù¼­, °¢ ±â¾÷ ¹× ¿¬±¸±â°üÀÇ ¿¬±¸ ÁøÇà »óȲ, À¯·Â ¾àÁ¦ ºñ±³ µîÀÇ Á¤º¸¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 1,000
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 108
Lip and Oral Cavity Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2018
»ùÇÃ
»óǰÄÚµå :227733
¼¼°è ±¸¼ø¾Ï ¹× ±¸°­¾Ï Ä¡·áÁ¦ ½ÃÀåÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡°ú °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀ» Æò°¡ºÐ¼®ÇßÀ¸¸ç, ÇâÈÄ ½ÃÀå°æÀï, ±â¾÷ °³¿ä¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 67
Dyskinesia Therapeutics - Pipeline Assessment and Market Forecasts to 2019
»ùÇÃ
»óǰÄÚµå :227728
¼¼°è ¿îµ¿Àå¾Ö Ä¡·áÁ¦ ½ÃÀåÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡°ú °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀ» Æò°¡ºÐ¼®ÇßÀ¸¸ç, ÇâÈÄ ½ÃÀå°æÀï, ±â¾÷ °³¿ä¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 61
Myocardial Infarction (MI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
»ùÇÃ
»óǰÄÚµå :227727
¼¼°è ½É±Ù°æ»ö(MI) Ä¡·áÁ¦ ½ÃÀåÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡°ú °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀ» Æò°¡ºÐ¼®ÇßÀ¸¸ç, ÇâÈÄ ½ÃÀå°æÀï, ±â¾÷ °³¿ä¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 114
Kawasaki Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018
»ùÇÃ
»óǰÄÚµå :227720
¼¼°è °¡¿Í»çŰº´ Ä¡·áÁ¦ ½ÃÀåÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡°ú °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀ» Æò°¡ºÐ¼®ÇßÀ¸¸ç, ÇâÈÄ ½ÃÀå°æÀï, ±â¾÷ °³¿ä¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 54
Male Hypogonadism Therapeutics - Pipeline Assessment and Market Forecasts to 2019
»ùÇÃ
»óǰÄÚµå :227719
¼¼°è ³²¼º ¼º¼±±â´É ÀúÇÏÁõ Ä¡·áÁ¦ ½ÃÀåÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡°ú °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀ» Æò°¡ºÐ¼®ÇßÀ¸¸ç, ÇâÈÄ ½ÃÀå°æÀï, ±â¾÷ °³¿ä¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 74
Generalized Anxiety Disorders (GAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
»ùÇÃ
»óǰÄÚµå :227718
¼¼°è ¹üºÒ¾ÈÀå¾Ö(CAD) Ä¡·áÁ¦ ½ÃÀåÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡°ú °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀ» Æò°¡ºÐ¼®ÇßÀ¸¸ç, ÇâÈÄ ½ÃÀå°æÀï, ±â¾÷ °³¿ä¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 62
Huntington's Disease (HD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
»ùÇÃ
»óǰÄÚµå :227717
¼¼°è ÇåÆÃÅϺ´(HD) Ä¡·áÁ¦ ½ÃÀåÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡°ú °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀ» Æò°¡ºÐ¼®ÇßÀ¸¸ç, ÇâÈÄ ½ÃÀå°æÀï, ±â¾÷ °³¿ä¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 69
Addiction Control Therapeutics - Pipeline Assessment and Market Forecasts to 2018
»ùÇÃ
»óǰÄÚµå :227646
¼¼°è ÀÇÁ¸Áõ Ä¡·áÁ¦ ½ÃÀåÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡°ú °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀ» Æò°¡ºÐ¼®ÇßÀ¸¸ç, ÇâÈÄ ½ÃÀå°æÀï, ±â¾÷ °³¿ä¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 75
Fibromyalgia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
»ùÇÃ
»óǰÄÚµå :227645
¼¼°è ¼¶À¯±ÙÀ°Åë Ä¡·áÁ¦ ½ÃÀåÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡°ú °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀ» Æò°¡ºÐ¼®ÇßÀ¸¸ç, ÇâÈÄ ½ÃÀå°æÀï, ±â¾÷ °³¿ä¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 71
Bronchitis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
»ùÇÃ
»óǰÄÚµå :227644
¼¼°è ±â°üÁö¿° Ä¡·áÁ¦ ½ÃÀåÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡°ú °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀ» Æò°¡ºÐ¼®ÇßÀ¸¸ç, ÇâÈÄ ½ÃÀå°æÀï, ±â¾÷ °³¿ä¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 120
Acute Coronary Syndrome (ACS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
»ùÇÃ
»óǰÄÚµå :227642
¼¼°è ±Þ¼º °ü»óµ¿¸Æ ÁõÈıº(ACS) Ä¡·áÁ¦ ½ÃÀåÀÇ ÆÄÀÌÇÁ¶óÀÎ ºÐ¼® ¹× ½ÃÀå ¿¹Ãø, ½ÃÀåÀÇ Æ¯Â¡°ú °æÀï, ÆÄÀÌÇÁ¶óÀÎ µîÀ» Æò°¡ºÐ¼®ÇßÀ¸¸ç, ÇâÈÄ ½ÃÀå°æÀï, ±â¾÷ °³¿ä¸¦ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 3,500
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 107
»ùÇÃ
»óǰÄÚµå :180369
È­»ó Ä¡·áÁ¦¿¡ ´ëÇÑ ÀÓ»ó½ÃÇè µ¿ÇâÀ» Á¶»çÇϰí ÀÓ»ó½ÃÇè °Ç¼ö ¹× ÇÇÇèÀÚ ¼ö, ´Ü°èº°¡¤»óź° ÀÓ»ó½ÃÇè, À¯¸Á ±â¾÷, °³¹ß ÁßÀÎ Ä¡·áÁ¦ Á¤º¸, ÀÓ»ó½ÃÇè ÇÁ·ÎÆÄÀÏ µîÀ» ÀüÇØµå¸³´Ï´Ù.
... ´õº¸±â
°¡°Ý US $ 1,000
¹ßÇàÀÏ 2011³â 12¿ù
¸®¼­Ä¡»ç GlobalData
ÆäÀÌÁö¼ö Pages: 93